961 related articles for article (PubMed ID: 25242736)
21. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
22. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
Sonpavde G; Bhor M; Hennessy D; Bhowmik D; Shen L; Nicacio L; Rembert D; Yap M; Schnadig I
Clin Genitourin Cancer; 2015 Aug; 13(4):309-318. PubMed ID: 25743206
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
25. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH;
Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
[TBL] [Abstract][Full Text] [Related]
26. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES
Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; Maines F; Veccia A; Galligioni E
Urol Oncol; 2015 Jun; 33(6):265.e15-21. PubMed ID: 25907622
[TBL] [Abstract][Full Text] [Related]
29. Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.
Gunduz S; Bozcuk H; Yıldız M; Goksu SS; Uysal M; Arslan D; Tatlı AM; Mutlu H; Coşkun HS; Ozdogan M
Indian J Cancer; 2015; 52(4):658-60. PubMed ID: 26960509
[TBL] [Abstract][Full Text] [Related]
30. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
[TBL] [Abstract][Full Text] [Related]
31. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
32. Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Strauss A; Worst TS; Nuhn P; Bolenz C; Heinrich E
Urol Int; 2017; 99(4):414-421. PubMed ID: 28700990
[TBL] [Abstract][Full Text] [Related]
33. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
Cheng HH; Gulati R; Azad A; Nadal R; Twardowski P; Vaishampayan UN; Agarwal N; Heath EI; Pal SK; Rehman HT; Leiter A; Batten JA; Montgomery RB; Galsky MD; Antonarakis ES; Chi KN; Yu EY
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):122-7. PubMed ID: 25600186
[TBL] [Abstract][Full Text] [Related]
34. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Lebdai S; Basset V; Branchereau J; de La Taille A; Flamand V; Lebret T; Murez T; Neuzillet Y; Ploussard G; Audenet F
World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology).
Süner A; Aydın D; Hacıoğlu MB; Doğu GG; İmamoğlu GI; Menekşe S; Pilancı KN; Yazıcı ÖK; Koca D; Karaağaç M; Akyol M; Akman T; Ergen S; Avcı N; Kaçan T; Bozkurt O; Kefeli U; Urakçı Z; Araz M; Arpacı E; Harputlu H; Sevinç A
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1238-43. PubMed ID: 27097941
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.
Francini E; Sweeney CJ
Eur Urol; 2016 Sep; 70(3):410-2. PubMed ID: 27184379
[TBL] [Abstract][Full Text] [Related]
39. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany.
Wenzel M; Borkowetz A; Lieb V; Hoffmann MA; Borgmann H; Höfner T; Dotzauer R; Neuberger M; Worst TS; von Hardenberg J; Linxweiler J; Klümper N
Urol Oncol; 2022 Dec; 40(12):538.e7-538.e14. PubMed ID: 36244915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
